Related references
Note: Only part of the references are listed.Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Martin F. Bachmann et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Cytosolic accumulation of HPV16 E7 oligomers supports different transformation routes for the prototypic viral oncoprotein: The amyloid-cancer connection
Karina Dantur et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Papillomaviruses in the causation of human cancers - a brief historical account
Harald zur Hausen
VIROLOGY (2009)
Therapeutic human papillomavirus vaccines: current clinical trials and future directions
Chien-Fu Hung et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
The N-terminal module of HPV16 E7 is an intrinsically disordered domain that confers conformational and recognition plasticity to the oncoprotein
Maria M. Garcia-Alai et al.
BIOCHEMISTRY (2007)
HPV vaccines: the beginning of the end for cervical cancer
Graham R. Leggatt et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7
O. Ohlenschlaeger et al.
ONCOGENE (2006)
Protein intrinsic disorder and human papillomaviruses: Increased amount of disorder in E6 and E7 Oncoproteins from high risk HPVs
Vladimir N. Uversky et al.
JOURNAL OF PROTEOME RESEARCH (2006)
Chaperone holdase activity of human papillomavirus E7 oncoprotein
LG Alonso et al.
BIOCHEMISTRY (2006)
Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor
X Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Immunotherapeutic uses of CpG oligodeoxynucleotides
DM Klinman
NATURE REVIEWS IMMUNOLOGY (2004)
The HPV 16 E7 viral oncoprotein self-assembles into defined spherical oligomers
LG Alonso et al.
BIOCHEMISTRY (2004)
Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model
MJP Welters et al.
VACCINE (2004)
High-risk (HPV16) human papillomavirus E7 oncoprotein is highly stable and extended, with conformational transitions that could explain its multiple cellular binding partners
LG Alonso et al.
BIOCHEMISTRY (2002)
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
S Zwaveling et al.
JOURNAL OF IMMUNOLOGY (2002)
Activity of HspE7, a novel immunotherapy, in patients with anogenital warts
SE Goldstone et al.
DISEASES OF THE COLON & RECTUM (2002)
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
G Hartmann et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
